CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...
Vertex Pharmaceuticals Inc. closed 5.23% below its 52-week high of $519.88, which the company achieved on November 8th.
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...
FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...
Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...
Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...
Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...
The Israeli spyware company blacklisted over human rights concerns has hired the firm to provide strategic advice on cyber policy issues.
FDA finds benzene contamination, Tronox to close a pigment plant, Sofinnova launches a European biotech fund, and more ...
There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...
The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...